UNCY (Unicycive Therapeutics) Operating Cash Flow per Share : $-0.30 (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics Operating Cash Flow per Share?

Unicycive Therapeutics's operating cash flow per share for the three months ended in Mar. 2025 was $-0.07. Unicycive Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.30.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 4.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -47.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Unicycive Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

UNCY' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -134.1 Med: -63.6 Max: 4.7
Current: 4.7

During the past 6 years, Unicycive Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 4.70% per year. The lowest was -134.10% per year. And the median was -63.60% per year.

UNCY's 3-Year OCF Growth Rate is ranked worse than
54.64% of 1217 companies
in the Biotechnology industry
Industry Median: 9.3 vs UNCY: 4.70

Unicycive Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Unicycive Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unicycive Therapeutics Operating Cash Flow per Share Chart

Unicycive Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.17

-0.49

-1.04

-0.75

-0.43

Unicycive Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.19	-0.07	-0.10	-0.06	-0.07

Competitive Comparison of Unicycive Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Unicycive Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unicycive Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Unicycive Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Unicycive Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-28.575	/	66.985
	=	-0.43

Unicycive Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-8.903	/	123.835
	=	-0.07

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30

Unicycive Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Unicycive Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Unicycive Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022

Website

https://www.unicycive.com

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Executives

Sandeep Laumas	director	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra	director	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal	director	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek	other: EVP of Corporate Strategy	4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller	director	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend	officer: Chief Financial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta	officer: EVP, Pharmaceuticals and BD	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta	director, officer: CEO	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022